FGFR2 and intrahepatic cholangiocarcinoma: We utilized a series of patient-derived models to define the transcriptional response to inhibition of FGFR signaling in FGFR2-fusion+ ICC, both in vivo and in vitro (Fig. 1a and Table 1, see Methods for information on the FGFR inhibitors used).